Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: Case studies and literature review

American Journal of the Medical Sciences

Volumn 339, Issue 1, 2010, Pages 36-40

  Cole, Marion ^a   Strair, Roger ^b  

^a University of Medicine   (United States)

^b NONE

Author keywords

AML; Breast cancer; MDS

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; LETROZOLE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL TRIAL; GENE MUTATION; HODGKIN DISEASE; HUMAN; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; OVARY CANCER; PARTIAL MASTECTOMY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 75449120478     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181bedb74     Document Type: Article

References (28)

1. Renella R, Verkooijen HM, Fioretta G, et al. Increased risk of acute myeloid leukaemia after treatment for breast cancer. Breast 2006;15: 614-619
2. Bedard P, Cardoso F. Recent advances in adjuvant systemic therapy for early-stage breast cancer. Ann Oncol 2008;19(suppl 5):v122-v127.
3. Nimer SD. Myelodysplastic syndromes. Blood 2008;111:4841-4851
4. List A. New approaches to the treatment of myelodysplasia. Oncologist 2002;7(suppl 1):39-49.
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849
6. Sahin FI, Yilmaz Z, Karakuçs S, et al. t(8;16) AML developed subsequent to breast cancer therapy. Hematology 2006;11:153-155
7. Hortobagyi G. Adjuvant therapy for breast cancer. Annu Rev Med 2000;51:377-392
8. Andersen MK, Christiansen DH, Jensen BA, et al. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol 2001;114:539-543
9. Spector LG, Xie Y, Robison LL, et al. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev 2005;14:651-655
10. Leone G, Mele L, Pulsoni A, et al. The incidence of secondary leukemias. Haematologica 1999;84:937-945
11. Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007; 92:1389-1398
12. Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-1204
13. Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007;25:292-300.
14. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007;25:3871-3876
15. Hershman D, Neugut A, Jacobson J, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196-205.
16. Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986;4:830-837
17. Friedenson B. The BRCA 1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007;7:152.
18. Scardocci A, Guidi F, D'Alo' F, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy related acute myeloid leukemia. Br J Cancer 2006;95:1108-1113
19. Tester WJ, Kinsella TJ, Waller B, et al. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol 1984;2:762-769
20. Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosomal abnormalities pre-high-dose treatment in patients with leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 2001; 19:2472-2481
21. Petersen-Bjergaard J, Andersen MS, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology 2007;1:392-397
22. Larson R. Etiology and management of therapy-related myeloid leukemia. Hematology 2007;1:453-459
23. Weinstein I. Cell culture studies on the mechanism of action of chemical carcinogens and tumor promoters. In: Carcinogenesis: a comprehensive survey: the role of chemicals and radiation in the etiology of cancer, Vol.10. New York (NY): Raven Press; 1985.
24. Shih HA, Nathanson KL, Seal S, et al. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 2000;6:4259-4264
25. Fong P, Boss D, Yap T, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:1-12.
26. Gamet-Payrastre L. Signaling pathways and intracellular targets of sulforaphane mediating cell cycle arrest and apoptosis. Curr Cancer Drug Targets 2006;6:135-145
27. Wahidur Rahman KM, Ali S, Aboukameel A, et al. Inactivation of NF-kappaB by 3,3′-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007;6:2757-2765
28. Bhatnagar N, Li X, Chen Y, et al. 3,3′-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev Res 2009;2:581.